Types of RNA therapeutics.

Antisense oligonucleotide Aptamer Gene expression MRNA MiRNA RNA therapy Ribozyme SiRNA

Journal

Progress in molecular biology and translational science
ISSN: 1878-0814
Titre abrégé: Prog Mol Biol Transl Sci
Pays: Netherlands
ID NLM: 101498165

Informations de publication

Date de publication:
2024
Historique:
medline: 16 2 2024
pubmed: 16 2 2024
entrez: 15 2 2024
Statut: ppublish

Résumé

RNA therapy is one of the new treatments using small RNA molecules to target and regulate gene expression. It involves the application of synthetic or modified RNA molecules to inhibit the expression of disease-causing genes specifically. In other words, it silences genes and suppresses the transcription process. The main theory behind RNA therapy is that RNA molecules can prevent the translation into proteins by binding to specific messenger RNA (mRNA) molecules. By targeting disease-related mRNA molecules, RNA therapy can effectively silence or reduce the development of harmful proteins. There are different types of RNA molecules used in therapy, including small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamer, ribozyme, and antisense oligonucleotides (ASOs). These molecules are designed to complement specific mRNA sequences, allowing them to bind and degrade the targeted mRNA or prevent its translation into protein. Nanotechnology is also highlighted to increase the efficacy of RNA-based drugs. In this chapter, while examining various methods of RNA therapy, we discuss the advantages and challenges of each.

Identifiants

pubmed: 38360005
pii: S1877-1173(23)00204-1
doi: 10.1016/bs.pmbts.2023.12.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-63

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Pouya Goleij (P)

Department of Genetics, Sana Institute of Higher Education, Sari, Iran; USERN Office, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Mehregan Babamohamadi (M)

USERN Office, Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Biology, School of Natural Sciences, University of Tabriz, Tabriz, Iran; Stem Cell and Regenerative Medicine Innovation Center, Tehran University of Medical Sciences, Tehran, Iran.

Aryan Rezaee (A)

Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Pantea Majma Sanaye (PM)

School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.

Mohammad Amin Khazeei Tabari (MAK)

Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran; USERN Office, Mazandaran University of Medical Sciences, Sari, Iran.

Sarvin Sadreddini (S)

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Reza Arefnezhad (R)

Coenzyme R Research Institute, Tehran, Iran; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: Reza.aref1374@gmail.com.

Hossein Motedayyen (H)

Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: hmotedayyen@gmail.com.

Classifications MeSH